Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson’s disease: Results from a single-center trial

Abstract

Background: Hypotension can occur in patients receiving levodopa (L-dopa) treatment for parkinsonism. However, only few studies have focused on the characteristics of orthostatic hypotension (OH) induced by the L-dopa challenge test (LCT). This study aimed to investigate the characteristics and influencing factors of LCT-induced OH in a relatively large sample of patients with Parkinson’s disease (PD). Methods: Seventy-eight patients with PD without a previous diagnosis of OH underwent the LCT. Blood pressure (BP) in the supine and standing positions was measured before and 2 hours after the LCT. If diagnosed with OH, the patients’ BP was monitored again 3 hours after the LCT. The clinical features and demographics of the patients were analyzed. Results: Eight patients were diagnosed with OH 2 hours after the LCT (median dose of 375 mg L-dopa/benserazide; incidence = 10.3%). One patient without symptoms had OH 3 hours after the LCT. Compared with patients without OH, patients with OH had lower 1- and 3-minutes standing systolic BP and 1-minute standing diastolic BP at baseline and 2 hours after the LCT. Patients in the OH group were of older age (65.31 ± 4.17 years vs 59.74 ± 5.55years) and had lower Montreal Cognitive Assessment scores (17.5 vs 24) and higher L-dopa/benserazide levels (375 [250, 500] mg vs 250 [125, 500] mg). Older age markedly increased the odds of having LCT-induced OH (odds ratio, 1.451; 95% confidence interval, 1.055–1.995; P = .022). Conclusions: LCT increased the odds of OH in non-OH PD, causing symptomatic OH in 10.3% of patients in our study, thereby raising safety concerns. Increase in age was observed to be a risk factor for LCT-induced OH in PD patients. A study with a larger sample size is warranted to confirm our results. Trial registration number: Clinical Trials Registry under ChiCTR2200055707. Date of registration: January 16, 2022.

Unique Brain Network Identification Number for Parkinson’s and Healthy Individuals Using Structural MRI

“…It may assist researchers and physicians in offering age-specific treatments. Anti-aging medicines might open new doors for the creation of disease-modifying therapeutics for PD [ 46 , 47 ] to interfere with the pathophysiology of the disorder [ 48 , 49 ]. We assume our investigation may play a new role in assisting researchers to understand variation in connections across ages.…”

Parkinson’s Disease: A Narrative Review on Potential Molecular Mechanisms of Sleep Disturbances, REM Behavior Disorder, and Melatonin

“…Unfortunately, and with an aging population, it has been estimated that the prevalence and incidence of PD may increase by more than 30% by 2030 [4]. PD is associated with a high risk of disability that is mostly associated with non-motor symptoms, which are difficult to treat or manage [5]. Bradykinesia, rigidity, and tremor at rest are the principal motor symptoms of PD patients [6].…”